相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Plasma levels of apolipoproteins C-III, A-IV, and E are independently associated with stable atherosclerotic cardiovascular disease
Julia Dittrich et al.
ATHEROSCLEROSIS (2019)
Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease
Brian A. Ference et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
Jordan Fulcher et al.
LANCET (2019)
Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry
Kornelia Kotseva et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2019)
Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association
Connie B. Newman et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Scott M. Grundy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk
Julius L. Katzmann et al.
PATIENT PREFERENCE AND ADHERENCE (2019)
Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena
Sarah Costantino et al.
EUROPEAN HEART JOURNAL (2018)
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
Ulf Landmesser et al.
EUROPEAN HEART JOURNAL (2018)
Reduction of low density lipoprotein- cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2018)
Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
Christie M. Ballantyne et al.
ATHEROSCLEROSIS (2018)
Characteristics of patients prescribed Evolocumab in Europe. Does clinical use match clinical guidelines?
K. Ray et al.
EUROPEAN HEART JOURNAL (2018)
Pathological phenotypes of LDL particles
Ulrich Laufs et al.
EUROPEAN HEART JOURNAL (2018)
Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, ismodifiable, and associates with future cardiovascular deaths
Maija Ruuth et al.
EUROPEAN HEART JOURNAL (2018)
Cardiovascular disease: The rise of the genetic risk score
Joshua W. Knowles et al.
PLOS MEDICINE (2018)
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
Amit V. Khera et al.
NATURE GENETICS (2018)
Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease: Results From the Cooper Center Longitudinal Study
Shuaib M. Abdullah et al.
CIRCULATION (2018)
Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults Implications for Primary Prevention
Michael Inouye et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract
Francois Mach et al.
EUROPEAN HEART JOURNAL (2018)
Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins
Kathleen M. Fox et al.
CLINICAL RESEARCH IN CARDIOLOGY (2018)
Vaccination to prevent atherosclerotic cardiovascular diseases
Ulrich Laufs et al.
EUROPEAN HEART JOURNAL (2017)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2017)
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
Christine Landlinger et al.
EUROPEAN HEART JOURNAL (2017)
Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk
Brian A. Ference et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Individualized lipid-lowering therapy to further reduce residual cardiovascular risk
Oliver Weingaertner et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2017)
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Robert P. Giugliano et al.
LANCET (2017)
Cognitive Function in a Randomized Trial of Evolocumab
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol A Prespecified Analysis of the IMPROVE-IT Trial
Robert P. Giugliano et al.
JAMA CARDIOLOGY (2017)
Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting
Pradeep Natarajan et al.
CIRCULATION (2017)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE
Paul S. Jellinger et al.
ENDOCRINE PRACTICE (2017)
EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries
Kornelia Kotseva et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2016)
Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries - Findings from the EUROASPIRE IV survey
Z. Reiner et al.
ATHEROSCLEROSIS (2016)
Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy 20-Year Follow-Up of West of Scotland Coronary Prevention Study
Ian Ford et al.
CIRCULATION (2016)
Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk
Ulrich Laufs et al.
CLINICAL RESEARCH IN CARDIOLOGY (2016)
Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase
Ozlem Bilen et al.
CURRENT ATHEROSCLEROSIS REPORTS (2016)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano et al.
EUROPEAN HEART JOURNAL (2016)
Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes A Meta-analysis
Luca A. Lotta et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
Amit V. Khera et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Brian A. Ference et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Rooted in risk: genetic predisposition for low-density lipoprotein cholesterol level associates with diminished low-density lipoprotein cholesterol response to statin treatment
Roelof A. J. Smit et al.
PHARMACOGENOMICS (2016)
Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease
Ann Marie Navar-Boggan et al.
CIRCULATION (2015)
Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps
Brian A. Ference
CURRENT OPINION IN LIPIDOLOGY (2015)
Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both
Brian A. Ference et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials
Jessica L. Mega et al.
LANCET (2015)
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials
Jordan Fulcher et al.
LANCET (2015)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
New metrics needed to visualize the long-term impact of early LDL-C lowering on the cardiovascular disease trajectory
Chris J. Packard et al.
VASCULAR PHARMACOLOGY (2015)
Mendelian randomization: genetic anchors for causal inference in epidemiological studies
George Davey Smith et al.
HUMAN MOLECULAR GENETICS (2014)
Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease
Nathan O. Stitziel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins
Iris Postmus et al.
NATURE COMMUNICATIONS (2014)
Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease
Michael Boehm et al.
AMERICAN HEART JOURNAL (2013)
Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy
Peter Libby
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Meta-Analysis of Comparison of Effectiveness of Lowering Apolipoprotein B Versus Low-Density Lipoprotein Cholesterol and Nonhigh-Density Lipoprotein Cholesterol for Cardiovascular Risk Reduction in Randomized Trials
Jennifer G. Robinson et al.
AMERICAN JOURNAL OF CARDIOLOGY (2012)
Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease A Mendelian Randomization Analysis
Brian A. Ference et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Everyone under statin?
Helene Vaillant-Roussel et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2012)
Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin-Treated Subjects From 3 Data Sources: A Retrospective Analysis
Peter H. Jones et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2012)
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
B. Mihaylova et al.
LANCET (2012)
Strategies to improve drug adherence
Ulrich Laufs et al.
EUROPEAN HEART JOURNAL (2011)
Nonoptimal Lipids Commonly Present in Young Adults and Coronary Calcium Later in Life: The CARDIA (Coronary Artery Risk Development in Young Adults) Study
Mark J. Pletcher et al.
ANNALS OF INTERNAL MEDICINE (2010)
Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents A Meta-Analysis
Ajay K. Gupta et al.
HYPERTENSION (2010)
Continuation of Statin Treatment and All-Cause Mortality A Population-Based Cohort Study
Varda Shalev et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
分享论文
